Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 18/20 | 0.54 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30672031 | 1.00 | AGTR2 (0.54) | AGTR2AGTR1CYP3A4GRM2 | |
| SCHEMBL30672029 | 0.93 | AGTR2 (0.51) | AGTR2AGTR1 | |
| SCHEMBL29958687 | 0.93 | AGTR2 (0.51) | AGTR2AGTR1 | |
| SCHEMBL29958604 | 0.91 | AGTR2 (0.48) | AGTR2AGTR1CYP3A4 | |
| SCHEMBL29958531 | 0.90 | AGTR2 (0.62) | AGTR2AGTR1 | |
| SCHEMBL29958672 | 0.90 | AGTR2 (0.49) | AGTR2AGTR1 | |
| SCHEMBL29958721 | 0.90 | AGTR2 (0.56) | AGTR2AGTR1CYP3A4 | |
| SCHEMBL25576366 | 0.90 | AGTR2 (0.56) | AGTR2AGTR1CYP3A4 | |
| SCHEMBL30195042 | 0.86 | AGTR2 (0.40) | AGTR2GRM2 | |
| SCHEMBL30672030 | 0.85 | AGTR2 (0.52) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182461-A1 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | VICORE PHARMA AB (SE) | 2024-06-06 | — | — | US | claimed |
| EP-4313953-A1 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | Vicore Pharma AB (SE) | 2024-02-07 | — | — | EP | claimed |
| WO-2022200785-A1 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | VICORE PHARMA AB (SE) | 2022-09-29 | — | — | WO | claimed |
| US-20240182461-A1 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | VICORE PHARMA AB (SE) | 2024-06-06 | — | — | US | disclosed |
| EP-4313953-A1 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | Vicore Pharma AB (SE) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022200785-A1 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | VICORE PHARMA AB (SE) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182461-A1 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | AGTR1, AGTR2, MSR1 | AGTR2 2/4885AGTR1 1/4885CYP3A4 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.